PFE.N
Latest Trade
35.48USDChange
0.20(+0.57%)Volume
7,454,210Today's Range
-
35.5352 Week Range
-
40.93As of on the New York Stock Exchange ∙ Minimum 15 minute delay
Previous Close | 35.28 |
|---|---|
Open | 35.21 |
Volume | 7,454,210 |
3M AVG Volume | 485.73 |
Today's High | 35.53 |
Today's Low | 34.84 |
52 Week High | 40.93 |
52 Week Low | 27.89 |
Shares Out (MIL) | 5,556.88 |
Market Cap (MIL) | 197,158.10 |
Forward P/E | -- |
Dividend (Yield %) | 4.28 |
Mylan Says Combination With Upjohn Expected To Close On November 16
Pfizer Inc Reports Adjusted Earning Of $0.72 Per Share
FDA Grants Priority Review And EMA Accepts Regulatory Submission For Pfizer's Abrocitinib
Pfizer Inc. (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). IH focuses on developing and commercializing medicines and vaccines. IH therapeutic areas include internal medicine, vaccines, oncology, inflammation and immunology, rare diseases and consumer healthcare. EH includes legacy brands, branded generics, generic sterile injectable products, biosimilars and infusion systems. EH also includes a research and development (R&D) organization, as well as its contract manufacturing business. Its brands include Prevnar 13, Xeljanz, Eliquis, Lipitor, Celebrex, Pristiq and Viagra.
Industry
Biotechnology & Drugs
Executive Leadership
Albert Bourla
Chairman of the Board, Chief Executive Officer
John D. Young
Chief Business Officer, Group President
Frank A. D'Amelio
Chief Financial Officer, Executive Vice President - Business Operations and Global Supply
Angela Hwang
Group President, Pfizer Biopharmaceuticals Group
Dawn Rogers
Chief Human Resource Officer, Executive Vice President
Price To Earnings (TTM) | 23.85 |
|---|---|
Price To Sales (TTM) | 4.05 |
Price To Book (MRQ) | -- |
Price To Cash Flow (TTM) | 15.00 |
Total Debt To Equity (MRQ) | -- |
LT Debt To Equity (MRQ) | -- |
Return on Investment (TTM) | -- |
Return on Equity (TTM) | -- |
The U.S. Federal Trade Commission said on Friday that it had approved generic drugmaker Mylan NV's <MYL.O> planned purchase of Pfizer's <PFE.N> Upjohn, subject to conditions.
Britain's health regulator has started accelerated reviews for COVID-19 vaccine candidates from Pfizer Inc and AstraZeneca Plc, according to a Bloomberg News report on Friday.
Britain's health regulator has started accelerated reviews for COVID-19 vaccine candidates from Pfizer Inc and AstraZeneca Plc, according to a Bloomberg report on Friday.
(Adds Vaxart, updates AstraZeneca, Moderna, J&J, Bharat Biotech, Russia's vaccine) Oct 29 (Reuters) - Pfizer and German partner BioNTech, along with Moderna and AstraZeneca, are at the forefront in the race to successfully develop a safe and effective COVID-19 vaccine. There...
Senior sources in the British government expect that a verdict on whether Pfizer Inc-backed COVID-19 vaccine works will be available before the results are in on AstraZeneca Plc's competing vaccine, the Times reported.
Senior sources in the British government expect a verdict on whether Pfizer Inc and BioNTech SE's COVID-19 vaccine works will be available before AstraZeneca Plc's competing vaccine, the Times reported.
* Indexes: Dow down 0.5%, S&P down 0.1%, Nasdaq up 0.5% (Updates to early afternoon)
Pfizer Inc's <PFE.N> Chief Executive Albert Bourla said on Tuesday that once it knows whether the vaccine candidate it is developing with Germany's BioNTech SE <22UAy.F> works, it could be a week before it lets the public know, making it unlikely it will release data before...
Drugmaker Pfizer Inc <PFE.N> said on Tuesday it does not yet have data from the late-stage trial of the COVID-19 vaccine it is developing with Germany's BioNTech SE <22UAy.F>, and provided a timeline that makes its release unlikely ahead of the Nov. 3 U.S. presidential election.Pfizer...
* Indexes: Dow down 0.28%, S&P down 0.03%, Nasdaq up 0.56% (Adds comment, details; updates prices)
Pfizer Inc's Chief Executive Albert Bourla said on Tuesday that once it knows whether the vaccine candidate it is developing with Germany's BioNTech SE works, it could be a week before it lets the public know, making it unlikely it will release data before the Nov. 3 presidential...
* Indexes: Dow down 0.26%, S&P flat, Nasdaq up 0.47% (Updates to market open)
Pfizer Inc on Tuesday reported a 4.3% drop in third-quarter sales, hurt by increased competition for its off-patent pain drug Lyrica and lower demand for some of its treatments during the COVID-19 pandemic.
The United States is likely to have enough safe and effective COVID-19 vaccines available to inoculate the most vulnerable Americans by the end of 2020, Health and Human Services Secretary Alex Azar said on Wednesday.
The United States is likely to have enough safe and effective COVID-19 vaccines available to inoculate the most vulnerable Americans by the end of 2020, Health and Human Services Secretary Alex Azar said on Wednesday.
Pfizer Inc <PFE.N> and BioNTech SE announced on Tuesday the start in Japan of combined Phase I and Phase II clinical trials of their mRNA vaccine candidate against the coronavirus.
Asian markets advanced toward a recent 2-1/2-year peak on Monday powered by hopes of a U.S. fiscal package and expectations of a coronavirus vaccine by the end of this year, though gains were held back by weaker-than-expected Chinese economic data.
Asian markets advanced toward a recent 2-1/2-year peak on Monday powered by hopes of a U.S fiscal package and expectations of a coronavirus vaccine by the end of this year, though weaker-than-expected Chinese data capped gains.
Asian markets started higher on Monday, buoyed by hopes of a U.S fiscal package before the U.S. presidential elections next month and expectations of a coronavirus vaccine by the end of this year, though the mood was still cautious as infections jump.
Pfizer Inc <PFE.N> said on Friday it could file in late November for U.S. authorization of the COVID-19 vaccine it is developing, suggesting that a vaccine could potentially be available in the United States by the end of the year.
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.